SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease
March 18, 2024 03:00 ET
|
Senisca Ltd
SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease £3.7 million seed financing supported by consortium of new and...
SENISCA appoints Dr. Sarah Cole as Chief Executive Officer
November 02, 2023 03:00 ET
|
Senisca Ltd
SENISCA appoints Dr. Sarah Cole as Chief Executive Officer Exeter, UK — 02 November 2023: SENISCA SENISCA, a biotechnology company developing RNA based therapeutics to reverse cellular senescence and...
SENISCA shortlisted for 2022/2023 Nature Spinoff prize
May 25, 2023 03:00 ET
|
Senisca Ltd
SENISCA shortlisted for 2022/2023 Nature Spinoff prize Exeter, UK – 25 May 2023: SENISCA, a UK biotechnology company developing RNA based therapeutics to reverse cellular senescence and target the...